首页> 美国卫生研究院文献>Aging (Albany NY) >Targeting nerve growth factor a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs
【2h】

Targeting nerve growth factor a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs

机译:靶向神经生长因子一种治疗骨关节炎的新选择:具有传统毒品的比较疗效和安全性的网络荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective: Osteoarthritis (OA) is the most common joint disease and leading cause of pain and disability in the elderly population. Most guidelines recommend the use of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids for the non-operative treatment of OA. Monoclonal nerve growth factor (NGF) antibodies are new drugs with the potential to provide pain relief and functional improvement in OA. We compared the efficacy (pain reduction and functional improvement), and safety of monoclonal NGF antibodies with NSAIDs and opioids in the treatment of OA with a Bayesian network meta-analysis.
机译:目的:骨关节炎(OA)是老年人口疼痛和残疾的最常见的联合疾病和致病原因。大多数指南建议使用非甾体类抗炎药(NSAIDS)和阿片类药物来治疗OA的不可操作。单克隆神经生长因子(NGF)抗体是新药,其潜力可以在OA中提供疼痛缓解和功能性改进。我们比较了用NSAID和阿片类药物治疗OA的单克隆NGF抗体的疗效(疼痛降低和功能性改进),以及贝叶斯网络荟萃分析的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号